Severe Cerebral Vasospasm and Childhood Arterial Ischemic Stroke After Intrathecal Cytarabine

Daniel Tibussek, MD, a,b Rungrote Natesirinilkul, MD, c Lisa R. Sun, MD, d Bruce A. Wasserman, MD, e Leonardo R. Brandão, MD, MSc, f Gabrielle deVeber, MD, MHS* a

abstract

We report on 2 patients who developed widespread cerebral vasospasm and arterial ischemic strokes (AIS) after application of intrathecal (IT) cytarabine. In a 3-year-old child with acute lymphoblastic leukemia (ALL), left leg weakness, hyperreflexia, and clonus were noted 4 days after her first dose of IT cytarabine during the induction phase of her chemotherapy. Cerebral MRI revealed multiple acute cerebral ischemic infarcts and widespread cerebral vasospasm. A 5-year-old girl complained of right arm and leg pain and began limping 11 days after IT cytarabine. Symptoms progressed to right dense hemiplegia, left gaze deviation, headache, and speech arrest. MRI revealed 2 large cortical areas of diffusion restriction in the right frontal and left parietal lobes. Cerebral magnetic resonance angiography (MRA) showed irregular narrowing affecting much of the intracranial arterial circulation. Although the first child fully recovered from her neurologic symptoms, the second patient had persistent hemiplegia on follow-up. Including this report, there are now 4 pediatric ALL cases of severe cerebral vasospasm and AIS in the context of IT cytarabine administration, strongly suggesting a true association. Differential diagnosis and management issues are discussed. Along with the more widespread use of MRI and MRA, the true frequency of this severe adverse effect will become clearer in future. For any child with neurologic symptoms within hours or days of receiving IT cytarabine, a low threshold for cerebral imaging with MRI and MRA is recommended.

Neurologic adverse effects of chemotherapy drugs are relatively common. Stroke has been related to chemotherapy both in children and adults.1

We report on 2 children diagnosed with precursor B-cell acute lymphoblastic leukemia (ALL) who developed acute ischemic strokes (AIS) after intrathecal cytarabine.

CASE REPORTS

Case 1

A previously healthy 3-year-old girl presented with a 1-week history of cervical lymphadenopathy and pallor. On admission, the remainder of her physical examination including neurologic examination was normal. Pancytopenia was found; hemoglobin 23 g/L, platelet count 41 × 10^9/L, white blood cell count 13.1 × 10^9/L, absolute neutrophil count 1.18 × 10^9/L, and blast cell count 7.73 × 10^9/L. A peripheral blood smear, flow cytometry, and bone marrow examination showed evidence of precursor B-cell ALL. Cerebrospinal fluid was normal with no evidence of blast cells. Coagulation testing was normal. She was diagnosed with standard-risk ALL.
Treatment was initiated according to the Children’s Oncology Group AALL 0932 protocol, including oral dexamethasone 2 mg oral twice daily for 28 days (started on day 1 of the protocol); 70 mg of intrathecal (IT) cytarabine on day 1; intravenous (IV) vincristine 0.9 mg on days 1, 8, 15, and 21; and IV peg-asparaginase (PEG-ASP) 1700 U on day 4. Four days after her IT cytarabine, she refused to walk, reporting a “funny feeling” in her left foot. Left leg weakness, hyperreflexia, and clonus were noted. She was afebrile, and no seizures had been observed. Arterial hypertension was found, with a maximum blood pressure of 130 mm Hg (systolic, >95 percentile) for systolic and 88 mm Hg (diastolic, >95 percentile). Hypertension was treated with nifedipine.

A cerebral MRI and magnetic resonance angiography (MRA) revealed multiple small acute infarcts in the right frontal and perirolandic region with multiple foci of narrowing and beaded appearance involving the large cerebral arteries (Fig 1).

Echocardiography, renal ultrasound, ophthalmologic examination, and electroencephalography all revealed normal findings. No evidence for systemic vasculitis was found. There was no family history of migraine or thrombosis.

Treatment with unfractionated heparin was initiated, and her IT cytarabine was omitted. She was discharged 8 days after stroke onset with low molecular weight heparin (LMWH). However, she developed lower gastrointestinal bleeding. LMWH was stopped, and protamine sulfate was administered. Due to a thrombocytopenia at 66 × 10⁹/L, low fibrinogen circulating level at 0.3 g/L, prolonged international normalized ratio at 2.2, and activated partial thromboplastin time at 44 seconds, she required replacement therapy with multiple blood products.

No source of bleeding could be identified. Gastrointestinal bleeding eventually stopped, and she resumed her chemotherapy protocol.

A follow-up MRA 5 weeks after stroke onset showed marked improvement of her arterial narrowing. She was discharged without focal neurologic deficit.

Case 2

A 5-year-old previously healthy girl presented with fatigue, fever, and bilateral leg pain. On presentation, neurologic examination was normal. Complete blood count revealed peripheral blasts, and bone marrow biopsy was diagnostic for standard-risk precursor B-cell ALL. Induction chemotherapy per protocol Children’s Oncology Group ALL 0932 was initiated. The patient received oral dexamethasone 2 mg twice daily for 28 days (started on day 1 of the protocol); IT cytarabine 70 mg on day 1; IV vincristine 1 mg on days 1, 8, 15, and 21; IV PEG-ASP 1725 U on day 4; and IT methotrexate 12 mg on day 8. On day 11 of induction, she complained of right arm and leg pain and began limping. Symptoms progressed to include dense right hemiplegia, left gaze deviation, speech arrest, and lethargy. On arrival in the emergency department, blood pressure was 109/73 mm Hg (90 percentile/95 percentile). Forced gaze deviation to the left was noted. Motor testing revealed 1/5 strength in the right arm and leg, whereas left hemibody strength was full. Right-sided hyperreflexia and upgoing right toe were noted. MRI at that time revealed multiple small acute infarcts in the right frontal and perirolandic region.

![Image](http://pediatrics.aappublications.org/)

FIGURE 1

Case 1. A, Time-of-flight MRA with multiple foci of stenoses with beaded appearance of the A2 segment of the anterior cerebri artery and branches of the middle cerebral arteries (red arrows). B and C, Acute small infarcts indicated by diffusion-weighted imaging–positive foci around the right precentral gyrus and cingulate gyrus.
revealed 2 large cortical areas of diffusion restriction in the right frontal and left parietal lobes. MRA showed irregular narrowing affecting much of the intracranial arterial circulation (Fig 2).

Echocardiogram was normal. Laboratory studies, including hypercoagulability panel, erythrocyte sedimentation rate, antinuclear antibody, antineutrophil cytoplasmic antibody, and myeloperoxidase, were negative. The patient has no family history of hypercoagulability or migraine.

No further IT cytarabine was given. PEG-ASP was held until repeated MRA showed resolution of vasculopathy. She missed 1 dose but has been receiving further PEG-ASP doses without any problems.

She was started on gabapentin for pain and aspirin 81 mg daily for stroke prophylaxis.

Follow-up MRA on day 36 of induction showed significant improvement in the vasculopathy, although arterial irregularities were still noted with some areas of progression (Fig 2). Postcontrast 3-dimensional high-resolution black blood MRI demonstrated no abnormal vessel wall enhancement seen on long-axis reconstructions of the right MCA (E and F; anterior-posterior oblique and axial views, respectively) and the left duplicated posterior cerebral artery (G, arrows), supporting vasospasm rather than an inflammatory vasculopathy.

FIGURE 2
Case 2: maximum intensity projection (MIP) images from three-dimensional time-of-flight MRAs acquired on day 12 (A and B) and day 36 of induction (C and D) in anterior-posterior oblique and axial views, respectively. Partial improvement in luminal irregularity involving the right middle cerebral artery (A and C, arrows) and anterior cerebral artery (A and C, arrowheads) vessels and improvement of left middle cerebral artery stenosis (B and D, arrows) and of left accessory posterior cerebral artery irregularity (B and D, arrowheads) was observed. The improved appearance was exaggerated by the higher resolution used on follow-up imaging (0.63 × 1.25 × 1.4 mm3 at 1.5T vs 0.52 × 0.54 × 0.55 mm3 at 3T). Three-dimensional high isotropic resolution black blood MRIs demonstrated no abnormal vessel wall enhancement seen on long-axis reconstructions of the right MCA (E and F; anterior-posterior oblique and axial views, respectively) and the left duplicated posterior cerebral artery (G, arrows), supporting vasospasm rather than an inflammatory vasculopathy.

DISCUSSION
We report 2 pediatric cases of diffuse cerebral vasospasm complicated by AIS related to IT cytarabine treatment. Both cases show striking similarities to 2 previous pediatric reports (Table 1). A 7-year-old girl with precursor B-cell ALL developed acute encephalopathy, aphasia, incontinence, visual hallucinations, and right-sided weakness. MRA showed diffuse cerebral vasospasm and ischemic lesions in both frontal lobes extending to the left parietal lobe. The patient fully recovered without anticoagulation. MRA abnormalities had resolved after 4 months. A 7-year-old boy with precursor B-cell ALL complained of intermittent visual loss on day 2 after IT cytarabine, toe pain on day 7, and persistent right-sided leg weakness on day 10. Diffusion-weighted imaging changes were not reported, but MRA showed diffuse cerebral vasospasm involving the anterior and posterior circulation. In addition, T1-weighted images showed “multifocal acute leukencephalopathy,” and follow-up imaging revealed multifocal lacunar infarcts. A comparable adult case was published previously. A 54-year-old woman undergoing induction therapy for ALL treatment developed an encephalopathy after receiving IT cytarabine. MRI showed abnormalities consistent with posterior reversible encephalopathy syndrome (PRES) associated with prominent vasospasm on MRA.

Different chemotherapeutic drugs are related to stroke and cerebrovascular events. Our patients had been exposed to PEG-ASP, dexamethasone, vincristine, and IT cytarabine at the time of symptom onset. Cerebral sinus venous thrombosis has been frequently associated with PEG-ASP, especially if combined with steroids, cerebral hemorrhages, and PRES. Cerebral vasospasm has never been reported in the context of PEG-ASP. Vincristine is mainly related to peripheral neuropathies. AIS or cerebral sinus venous thrombosis secondary to vincristine treatment have not been published.
High-dose IV cytarabine has been reported to cause central nervous system toxicity, including seizures, encephalopathy, and acute cerebellar syndrome. Apart from the aforementioned pediatric cases, stroke has not been previously reported. Interestingly, diffuse brain hypoperfusion was found in a study of children who underwent single photon emission computed topography scan during high-dose cytarabine IV administration.

In our cases as well as those previously published, the MRA pattern was characterized by widespread cerebral vasospasm resembling reversible cerebral vasoconstriction syndrome (RCVS). However, the clinical histories in our cases are not typical for RCVS, which is extremely rare in early childhood. Neither the clinical history nor laboratory and MRI results in our patients were suggestive of meningitis or a primary angiitis of the central nervous system. In the absence of headache and presence of a negative family history, migraine was not considered a differential diagnosis.

The location, conformation, and persistence of the parenchymal lesions indicate that these were consistent with vaso-occlusive infarcts and not hypertensive encephalopathy or PRES. Thus, even though the exact pathomechanism leading to the development of cerebral vasospasms and consecutive AIS is difficult to be finally proved, we propose that toxic effects of IT cytarabine are the most plausible explanation in our patients. Arterial hypertension was a potential cofactor in case 1 but not case 2.

Our first patient was treated with anticoagulation. Aspirin was used in case 2. Both heparin and aspirin are treatment options for secondary stroke prevention in children. However, primary management is symptomatic, including identification and elimination of any precipitating or aggravating factors. Additional treatment may include analgesics, antiepileptic drugs for seizures, and treatment of arterial hypertension. Hypotension in the setting of cerebral vasoconstriction and cerebral infarction is potentially dangerous. Nimodipine was administered in our second case as well as 1 published case. However, evidence for the risks

<table>
<thead>
<tr>
<th>Age at stroke onset, y</th>
<th>7</th>
<th>7</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of leukemia</td>
<td>Precursor B-cell ALL</td>
<td>Precursor B-cell ALL</td>
<td>Precursor B-cell ALL</td>
</tr>
<tr>
<td>Chemotherapy protocol</td>
<td>COG AALL 0331</td>
<td>COG AALL 0532</td>
<td>COG AALL 0932</td>
</tr>
<tr>
<td>Dose of IT cytarabine</td>
<td>70 mg</td>
<td>70 mg</td>
<td>70 mg</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Aphasia, incontinence, visual hallucinations, right-side weakness</td>
<td>Headache, visual loss, right-side weakness</td>
<td>Left leg weakness, dysaesthesia left leg</td>
</tr>
<tr>
<td>Symptom onset after IT cytarabine application</td>
<td>3 d</td>
<td>10 d</td>
<td>4 d</td>
</tr>
<tr>
<td>MRA</td>
<td>Diffuse vasospasm, bilateral, subcortical frontal white matter</td>
<td>Diffuse vasospasm, multifocal cortical and subcortical white matter</td>
<td>Diffuse vasospasm, bilateral cortical</td>
</tr>
<tr>
<td>Stroke pattern</td>
<td>Bilateral, subcortical frontal white matter</td>
<td>Multifocal cortical and subcortical white matter</td>
<td>Diffuse vasospasm</td>
</tr>
<tr>
<td>Management</td>
<td>No medication</td>
<td>Nimodipine, LMWH, citicoline, antithrombin, fresh-frozen plasma</td>
<td>LMWH</td>
</tr>
<tr>
<td>Neurologic outcome</td>
<td>Full recovery</td>
<td>Full recovery</td>
<td>Full recovery</td>
</tr>
<tr>
<td>MRA brain follow-up of vasospasm</td>
<td>Improvement after 10 d, complete resolution after 4 mo</td>
<td>Marked improvement after 25 d</td>
<td>Marked improvement after 4 wk</td>
</tr>
</tbody>
</table>

COG, Children’s Oncology Group.
and benefits of any drugs targeted at vasospasm, including nimodipine is not even available for the much more common RCVS in adulthood. Therefore, observation and symptomatic management may be reasonable after discontinuation of the precipitating drug. MRI/MRA and clinical follow-up is warranted to identify early signs of progression and persistence of vasospasm. Recovery is not always complete, as illustrated by our second case. Including this report, there are now 4 pediatric cases of severe cerebral vasospasm and AIS in the context of IT cytarabine administration in ALL patients, strongly suggesting a true association. Given the total number of patients treated with IT cytarabine, the overall incidence is probably low. However, this complication may be underdiagnosed. With more widespread use of MRI and MRA the true frequency of this severe adverse effect of cytarabine will become clearer in future. For any child with neurologic symptoms within hours or days of receiving IT cytarabine, a low threshold for cerebral imaging with MRI and MRA is recommended.

FINANCIAL DISCLOSURE: Dr Wasserman has a patent pending (no. 13/922,111) for the 3-dimensional black blood MRI imaging technique shown in Figure 2; the other authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

REFERENCES


Severe Cerebral Vasospasm and Childhood Arterial Ischemic Stroke After Intrathecal Cytarabine

Daniel Tibussek, Rungrote Natesrinilkul, Lisa R. Sun, Bruce A. Wasserman, Leonardo R. Brandão and Gabrielle deVeber

Pediatrics 2016;137;
DOI: 10.1542/peds.2015-2143 originally published online January 19, 2016;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/137/2/e20152143

References
This article cites 14 articles, 6 of which you can access for free at:
http://pediatrics.aappublications.org/content/137/2/e20152143.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Hematology/Oncology
http://classic.pediatrics.aappublications.org/cgi/collection/hematology_oncology_sub
Cancer/Neoplastic
http://classic.pediatrics.aappublications.org/cgi/collection/cancer_neoplastic_sub
Neurology
http://classic.pediatrics.aappublications.org/cgi/collection/neurology_sub
Neurologic Disorders
http://classic.pediatrics.aappublications.org/cgi/collection/neurologic_disorders_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .
Severe Cerebral Vasospasm and Childhood Arterial Ischemic Stroke After Intrathecal Cytarabine

Daniel Tibussek, Rungrote Natesirinilkul, Lisa R. Sun, Bruce A. Wasserman, Leonardo R. Brandão and Gabrielle deVeber

*Pediatrics* 2016;137;

DOI: 10.1542/peds.2015-2143 originally published online January 19, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/137/2/e20152143